Sara Mainardi
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 20, 2025
CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: August 15, 2025
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 20, 2024
With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors.
Journal: Cell reports. Medicine
Published: February 22, 2023
Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy.
Journal: Cancer discovery
Published: February 21, 2023
A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer.
Journal: Cell genomics
Published: February 13, 2023
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.
Journal: Molecular oncology
Published: September 17, 2022
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.
Journal: Cell reports. Medicine
Published: January 24, 2022
Inducing and exploiting vulnerabilities for the treatment of liver cancer.
Journal: Nature
Published: October 18, 2018
Last Updated: 09/26/2026